Last reviewed 2026-05-27 · How we verify

Tolebrutininb

Sanofi · discontinued Small molecule ✓ Verified May 2026

Tolebrutininb is a Small molecule drug developed by Sanofi. It is currently in discontinued development.

Tolebrutininb is being studied as a potential treatment for generalized Myasthenia Gravis. It is being compared to a placebo in clinical trials to assess its efficacy and safety.

At a glance

Generic name	Tolebrutininb
Sponsor	Sanofi
Modality	Small molecule
Therapeutic area	Other
Phase	discontinued

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tolebrutinib (SAR442168) in Adults With Generalized Myasthenia Gravis (MG) (Phase 3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tolebrutininb CI brief — competitive landscape report
Tolebrutininb updates RSS · CI watch RSS
Sanofi portfolio CI

Frequently asked questions about Tolebrutininb

What is Tolebrutininb?

Tolebrutininb is a Small molecule drug developed by Sanofi.

Who makes Tolebrutininb?

Tolebrutininb is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

What development phase is Tolebrutininb in?

Tolebrutininb is in discontinued.

Manufacturer: Sanofi — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing